NOV 08, 2020 7:30 AM PST

Psychedelic Mushrooms Effectively Treat Major Depression

WRITTEN BY: Annie Lennon

image

Over 17 million people in the US and 300 million people worldwide are estimated to have experienced major depression. Now, researchers from Johns Hopkins University have found that two doses of psilocybin, the psychoactive ingredient in ‘magic mushrooms’, coupled with psychotherapy, can significantly reduce depressive symptoms. 

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” says Alan Davis, assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. 

“Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.”

For the study, the researchers involved 24 people with a long-term history of depression, most of whom experienced persistent depressive symptoms for around two years prior to enrolling in the study. The average age of the participants was 39, while 16 were women, and 22 considered themselves as ‘white’. 

The treatment consisted of two psilocybin sessions lasting five hours each monitored by two clinicians taken two weeks apart between August 2017 and April 2019. Prior to the treatment and at one week and 4-week follow-ups from treatment completion, participants were assessed with a standard depression assessment tool known as the GRID-Hamilton Depression Rating Scale. 

All in all, 67% of participants showed more than a 50% reduction in depressive symptoms at a one-week follow-up. At the four-week follow-up, this number increased to 71% of participants. On top of this, at the four-week follow-up, 54% of participants no longer qualified for being depressed.

The researchers now say that they will follow the participants for another year to see how long the antidepressant effects of psilocybin-assisted psychotherapy last, and will report their results in a later publication. 

 

Sources: Neuroscience NewsNPR

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 20, 2020
Drug Discovery & Development
The Power of Extracellular Vesicles
OCT 20, 2020
The Power of Extracellular Vesicles
What are extracellular vesicles (EVs)? They are tiny nanometer sized messengers that transport themselves between cells ...
NOV 06, 2020
Drug Discovery & Development
New Vaccine Shows Promise for Herpes
NOV 06, 2020
New Vaccine Shows Promise for Herpes
The World Health Organization estimates that over 500 million people have Herpes Simplex Virus Type 2 (HSV-2), a sexuall ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 08, 2020
Cannabis Sciences
Can Cannabis Treat Epilepsy?
NOV 08, 2020
Can Cannabis Treat Epilepsy?
There has been growing interest in recent years for cannabis to treat central nervous system disorders. And so far, ther ...
NOV 20, 2020
Drug Discovery & Development
Hyperbaric Oxygen Treatments Reverse Aging
NOV 20, 2020
Hyperbaric Oxygen Treatments Reverse Aging
Researchers from Israel have found that hyperbaric oxygen treatments (HBOT) in healthy aging adults can prevent blood ce ...
DEC 03, 2020
Drug Discovery & Development
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
DEC 03, 2020
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
Last month, Oregon became the first state in the US to legalize psilocybin mushrooms as a therapeutic treatment. Now, th ...
Loading Comments...